KRAS and adenocarcinoma: Since adenocarcinomas—the tumor with the highest prevalence of the KRAS mutation [28]—occur at similar rates in LM (72.7%) and HM (85.7%) groups, we confirmed that KRAS mutations were associated with muscularity rather than tumor histopathology.